The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N. Louis,Arie Perry,Guido Reifenberger,Andreas von Deimling,Dominique Figarella-Branger,Webster K. Cavenee,Hiroko Ohgaki,Otmar D. Wiestler,Paul Kleihues,David W. Ellison +9 more
Reads0
Chats0
TLDR
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor and is hoped that it will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.Abstract:
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered. The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance. Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded. Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.read more
Citations
More filters
Journal ArticleDOI
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Jianfang Liu,Tara M. Lichtenberg,Katherine A Hoadley,Laila M. Poisson,Alexander J. Lazar,Andrew D. Cherniack,Albert J. Kovatich,Christopher C. Benz,Douglas A. Levine,Adrian V. Lee,Larsson Omberg,Denise M. Wolf,Craig D. Shriver,Vesteinn Thorsson,Hai Hu +14 more
TL;DR: These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale.
Journal ArticleDOI
New Technologies for Analysis of Extracellular Vesicles
TL;DR: This article aims to present a comprehensive and critical overview of emerging analytical technologies for EV detection and their clinical applications.
Journal ArticleDOI
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller,Martin J. van den Bent,Jörg C. Tonn,Roger Stupp,Matthias Preusser,Elizabeth Cohen-Jonathan-Moyal,Roger Henriksson,Emilie Le Rhun,Carmen Balana,Olivier Chinot,Martin Bendszus,Jaap C. Reijneveld,F. Dhermain,Pim J. French,Christine Marosi,Colin Watts,Ingela Oberg,Geoffrey J. Pilkington,Brigitta G. Baumert,Martin J.B. Taphoorn,Monika E. Hegi,Manfred Westphal,Guido Reifenberger,Riccardo Soffietti,Wolfgang Wick,Wolfgang Wick +25 more
TL;DR: The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas, based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline.
Journal ArticleDOI
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma
Itay Tirosh,Andrew S. Venteicher,Andrew S. Venteicher,Christine Hebert,Christine Hebert,Leah E. Escalante,Leah E. Escalante,Anoop P. Patel,Keren Yizhak,Keren Yizhak,Jonathan M. Fisher,Christopher Rodman,Christopher Mount,Mariella G. Filbin,Mariella G. Filbin,Cyril Neftel,Cyril Neftel,Niyati Desai,Jackson Nyman,Benjamin Izar,Christina C. Luo,Joshua M. Francis,Joshua M. Francis,Aanand A. Patel,Maristela L. Onozato,Nicolo Riggi,Kenneth J. Livak,David Gennert,Rahul Satija,Brian V. Nahed,William T. Curry,Robert L. Martuza,Ravindra Mylvaganam,A. John Iafrate,Matthew P. Frosch,Todd R. Golub,Todd R. Golub,Todd R. Golub,Miguel Rivera,Miguel Rivera,Gad Getz,Gad Getz,Orit Rozenblatt-Rosen,Daniel P. Cahill,Michelle Monje,Bradley E. Bernstein,Bradley E. Bernstein,David N. Louis,Aviv Regev,Aviv Regev,Mario L. Suvà,Mario L. Suvà +51 more
TL;DR: In this paper, the authors profile 4,347 single cells from six IDH1 or IDH2 mutant human oligodendrogliomas by RNA sequencing and reconstruct their developmental programs from genome-wide expression signatures.
Journal ArticleDOI
Management of glioblastoma: State of the art and future directions.
Aaron C. Tan,David M. Ashley,Giselle Y. Lopez,Michael D. Malinzak,Henry S. Friedman,Mustafa Khasraw +5 more
TL;DR: Supportive and palliative care remain important considerations throughout the disease course in the multimodality approach to management, and innovative clinical trial designs with biomarker-enrichment strategies are needed to ultimately improve the outcome of patients with glioblastoma.
References
More filters
Journal ArticleDOI
Histopathological grading of pediatric ependymoma: Reproducibility and clinical relevance in European trial cohorts
David W. Ellison,Mehmet Kocak,Dominique Figarella-Branger,Giangaspero Felice,Godfraind Catherine,Torsten Pietsch,Didier Frappaz,Maura Massimino,Jacques Grill,James M. Boyett,Richard Grundy +10 more
TL;DR: It is concluded that concordance on grading ependymomas can be improved by using a more prescribed scheme based on the WHO classification, and unfortunately, this appears to have utility in limited clinical settings.
Journal ArticleDOI
Nonsense Mutation and Inactivation of SMARCA4 (BRG1) in an Atypical Teratoid/Rhabdoid Tumor Showing Retained SMARCB1 (INI1) Expression
Martin Hasselblatt,Stefan Gesk,Florian Oyen,Sabrina Rossi,Elisabetta Viscardi,Felice Giangaspero,Felice Giangaspero,Caterina Giannini,Alexander R. Judkins,Alexander R. Judkins,Michael C. Frühwald,Tobias Obser,Reinhard Schneppenheim,Reiner Siebert,Werner Paulus +14 more
TL;DR: The case of a supratentorial AT/RT in a 9-month-old boy, which showed retained SMARCB1 staining on immunohistochemistry and lacked genetic alterations of SMarCB1, highlights the role of SMARCA4 in the pathogenesis of SM ARCB1-positive At/RT and the usefulness of antibodies directed against SMAR CA4 in this diagnostic setting.
Journal ArticleDOI
Molecular genetics of atypical teratoid/rhabdoid tumor.
TL;DR: This review summarizes what is currently known regarding the molecular genetics of RTs and describes how the hSNF5/INI1 protein is recruited to promoters of a large variety of genes involved in cell signaling, growth, and differentiation.
Journal ArticleDOI
Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
Caterina Giannini,Bernd W. Scheithauer,Amy L. Weaver,Peter C. Burger,Johan M. Kros,Sverre Mørk,M. B. Graeber,S. Bauserman,Jan C. Buckner,James Burton,R. Riepe,H. D. Tazelaar,Antonio G. Nascimento,Thomas B. Crotty,Gary L. Keeney,P. Pernicone,H. Altermatt +16 more
TL;DR: This study found few factors independently associated with cause specific-survival among morphological parameters, consistent with the present WHO stratification of oligodendrogliomas into low- and high-grade variants.
Journal ArticleDOI
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
Lori A. Ramkissoon,Peleg M. Horowitz,Justin M. Craig,Shakti Ramkissoon,Benjamin E. Rich,Steven E. Schumacher,Aaron McKenna,Michael S. Lawrence,Guillaume Bergthold,Priscilla K. Brastianos,Barbara Tabak,Matthew D. Ducar,Paul Van Hummelen,Laura E. MacConaill,Tina Pouissant-Young,Yoon Jae Cho,Hala Taha,Madeha Mahmoud,Daniel C. Bowers,Linda R. Margraf,Uri Tabori,Cynthia Hawkins,Roger J. Packer,D. Ashley Hill,Scott L. Pomeroy,Charles G. Eberhart,Ian F. Dunn,Liliana Goumnerova,Gad Getz,Jennifer A. Chan,Sandro Santagata,William C. Hahn,Charles D. Stiles,Azra H. Ligon,Mark W. Kieran,Rameen Beroukhim,Keith L. Ligon +36 more
TL;DR: Clinical relevant molecular subclasses of diffuse PLGGs are defined and a potential role for the MYB family is highlighted in the biology of low-grade gliomas.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
IDH1 and IDH2 Mutations in Gliomas
Hai Yan,D. Williams Parsons,Genglin Jin,Roger E. McLendon,B.K. Ahmed Rasheed,Weishi Yuan,Ivan Kos,Ines Batinic-Haberle,Siân Jones,Gregory J. Riggins,Henry S. Friedman,Allan H. Friedman,David A. Reardon,James E. Herndon,Kenneth W. Kinzler,Victor E. Velculescu,Bert Vogelstein,Darell D. Bigner +17 more
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G.W. Verhaak,Katherine A. Hoadley,Elizabeth Purdom,Victoria Wang,Yuan-yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd R. Golub,Jill P. Mesirov,Gabriele Alexe,Michael S. Lawrence,Michael O'Kelly,Pablo Tamayo,Barbara A. Weir,Stacey Gabriel,Wendy Winckler,Supriya Gupta,Lakshmi Jakkula,Heidi S. Feiler,J. Graeme Hodgson,C. David James,Jann N. Sarkaria,Cameron Brennan,Ari B. Kahn,Paul T. Spellman,Richard K. Wilson,Terence P. Speed,Terence P. Speed,Joe W. Gray,Matthew Meyerson,Gad Getz,Charles M. Perou,Charles M. Perou,D. Neil Hayes +34 more